Aortic Valve Disease

Cardiovascular
1
Pipeline Programs
4
Companies
7
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Artivion
ArtivionKENNESAW, GA
1 program
1
Apixaban 5 MGPhase 31 trial
Active Trials
NCT04142658TerminatedEst. Dec 2022
Abbott
AbbottABBOTT PARK, IL
5 programs
Artificial Mechanical Heart ValveN/A1 trial
PAR I - Patient-to-Annulus Relation IN/A1 trial
Trifecta GTN/A1 trial
Trifecta™ aortic bioprosthesisN/A1 trial
VAVGJN/A1 trial
Active Trials
NCT00590889Terminated807Est. Sep 2014
NCT02981004Completed304Est. Dec 2017
NCT03016169Completed358Est. Aug 2023
+2 more trials
Foldax
FoldaxUT - Salt Lake City
1 program
Foldax Tria Aortic ValveN/A1 trial
Active Trials
NCT03851068Active Not RecruitingEst. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
ArtivionApixaban 5 MG
AbbottVAVGJ
FoldaxFoldax Tria Aortic Valve
AbbottTrifecta GT
AbbottPAR I - Patient-to-Annulus Relation I
AbbottTrifecta™ aortic bioprosthesis
AbbottArtificial Mechanical Heart Valve

Clinical Trials (7)

Total enrollment: 2,880 patients across 7 trials

NCT04142658ArtivionApixaban 5 MG

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Start: May 2020Est. completion: Dec 2022
Phase 3Terminated
NCT04754217AbbottVAVGJ

Valved Graft PMCF Study

Start: Jul 2021Est. completion: Sep 2029260 patients
N/ARecruiting
NCT03851068FoldaxFoldax Tria Aortic Valve

Early Feasibility Study for the Foldax Tria Aortic Heart Valve

Start: Jun 2019Est. completion: Dec 2026
N/AActive Not Recruiting
NCT03016169AbbottTrifecta GT

Trifecta™ GT Post Market Clinical Follow-up

Start: Mar 2017Est. completion: Aug 2023358 patients
N/ACompleted
NCT02981004AbbottPAR I - Patient-to-Annulus Relation I

PAR I - Patient-to-Annulus Relation I

Start: Oct 2012Est. completion: Dec 2017304 patients
N/ACompleted
NCT01256710AbbottTrifecta™ aortic bioprosthesis

Trifecta™ Durability Study

Start: Jan 2011Est. completion: Mar 20211,151 patients
N/ATerminated
NCT00590889AbbottArtificial Mechanical Heart Valve

Artificial Valve Endocarditis Reduction Trial

Start: Jul 1998Est. completion: Sep 2014807 patients
N/ATerminated

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr

Associate Regulatory Affairs Specialist

Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr

Business Development Manager, Post Transplant, Cardio Thoracic

Thermo Fisher Scientific
Remote
Yesterday

Director, Medical Affairs

Abbott
Germany - Hesse - Eschborn
Yesterday

Therapy Development Manager

Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 2,880 patients
4 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)